Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Press Release

June 15, 2020

Staff and Attorneys Vote Sterne Kessler as a Washington Post “Top Workplace” for Seventh Consecutive Year

Sterne, Kessler, Goldstein & Fox P.L.L.C.

In the News

June 15, 2020

Black IP lawyers reveal struggles with systemic racism

Managing IP

Press Release

June 11, 2020

Durkin, Ellison, and Talley Again Named Among “Top 250 Women in IP” by Managing IP

Sterne, Kessler, Goldstein & Fox P.L.L.C.